Barclays PLC Buys 20,880 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Barclays PLC increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 298,445 shares of the biopharmaceutical company's stock after purchasing an additional 20,880 shares during the quarter. Barclays PLC owned about 0.18% of ACADIA Pharmaceuticals worth $5,477,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Norges Bank bought a new stake in ACADIA Pharmaceuticals during the 4th quarter worth approximately $25,555,000. Renaissance Technologies LLC increased its holdings in ACADIA Pharmaceuticals by 204.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock worth $22,507,000 after acquiring an additional 823,333 shares during the period. Great Lakes Advisors LLC purchased a new stake in ACADIA Pharmaceuticals in the 4th quarter worth approximately $9,909,000. Finally, Burney Co. bought a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $6,953,000. 96.71% of the stock is currently owned by institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares of the company's stock, valued at $320,756.85. This represents a 21.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares in the company, valued at approximately $969,957.45. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,169 shares of company stock worth $242,686 in the last three months. 28.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ACAD has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Finally, StockNews.com raised shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, March 8th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $23.87.

ACADIA Pharmaceuticals Trading Down 1.6 %

ACAD stock traded down $0.23 during midday trading on Tuesday, hitting $14.43. The company had a trading volume of 1,586,537 shares, compared to its average volume of 1,848,437. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 18.50 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $20.68. The stock's 50 day moving average price is $16.54 and its 200 day moving average price is $16.95.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.